Search Results for agency_names:"Health and Human Services Department"

The Food and Drug Administration (FDA) is hosting a workshop titled "Best Practices for Development and Application of Disease Progression Models," which is part of their performance commitment under the Prescription Drug User Fee Act of 2017. The workshop aims to discuss the best practices for creating disease progression models that can aid in drug development, and to explore current challenges and research needs in this area. The FDA is inviting the public to submit comments about areas of interest related to disease progression modeling to ensure a comprehensive discussion during the workshop. Comments must be submitted by March 26, 2021, and can be sent electronically or through written/paper submissions.

The Centers for Disease Control and Prevention (CDC) has submitted an information collection request for the National Notifiable Diseases Surveillance System (NNDSS) to be reviewed and approved by the Office of Management and Budget. This request, part of the Paperwork Reduction Act, focuses on collecting health-related data on reportable diseases from various jurisdictions, including 60 U.S. territories and freely associated states. The proposal includes new data collection for diseases like COVID-19 and Anthrax, and aims to enhance data quality and reduce data collection burdens through electronic means. The CDC encourages public comments on the information collection, emphasizing areas such as the necessity, accuracy, and burden of the proposed data gathering.

The Centers for Disease Control and Prevention (CDC) has submitted a request to revise the Behavioral Risk Factor Surveillance System (BRFSS) for approval by the Office of Management and Budget (OMB), as part of their compliance with the Paperwork Reduction Act of 1995. The BRFSS, which surveys health risk behaviors and conditions across all U.S. states and territories, plans to add an online survey option in addition to traditional phone interviews for 2025-2027. This system helps gather essential health data, and for most states, it's the primary source of such information. Public comments on this proposed data collection are welcome within 30 days of this notice's publication.

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) will hold a closed meeting of their Board of Scientific Counselors on April 23, 2025, from 8:15 a.m. to 3:45 p.m. This virtual meeting is closed to the public in order to discuss and review individual programs and projects, as well as personnel qualifications, in a way that ensures privacy. Interested individuals can contact Dr. Tamara N. Alliston for more information. This follows guidelines set by federal laws that allow certain meetings to remain private to protect personal information.

The Center for Scientific Review within the National Institutes of Health announced several closed meetings to review grant applications. These meetings will not be open to the public as they will discuss sensitive details like trade secrets and personal information. The meetings cover various topics, including bacterial-host interactions, vascular and hematological systems, and drug toxicity. All meetings will be held virtually from the National Institutes of Health in Bethesda, Maryland.

The National Institute on Drug Abuse (NIDA) will hold a closed meeting on May 6, 2025, of the Board of Scientific Counselors. The meeting will be virtual, running from 10:00 a.m. to 4:45 p.m., and is closed to the public to protect personal privacy, as it involves discussions on the qualifications and performance of individual researchers. The meeting will assess various NIDA programs and projects conducted by its members. For inquiries, Megan E. Bollinger and Deon Harvey are the contacts for more information.

The National Institutes of Health announced upcoming meetings by the National Institute on Minority Health and Health Disparities that will be closed to the public to protect confidential information. These meetings, scheduled for March 16, 22, and 26, 2021, will focus on reviewing and evaluating grant applications related to conference grants and HIV prevention and care. The meetings will be held virtually, and each has a specified contact person for more information. These closed sessions aim to discuss sensitive and private information, ensuring personal privacy is maintained.

The Food and Drug Administration (FDA) is seeking information on the production methods and ingredients used in making high-protein yogurt, including Greek yogurt, due to discrepancies with existing yogurt identity standards. This request aims to understand if different standards are needed to ensure consumer honesty and fair dealing, considering innovations and practices in the yogurt industry. The public can submit comments electronically or in writing until April 15, 2025. The FDA is particularly interested in consumer perceptions, industry practices, and the labeling of these high-protein yogurt products.

The National Heart, Lung, and Blood Institute announced that several meetings will be held in February 2025, but they will be closed to the public. These meetings are being organized to review grant applications and contract proposals, and they will be conducted virtually. The closed nature of the meetings is due to the potential disclosure of confidential information, such as trade secrets or personal data. Contact details for the Scientific Review Officers handling each meeting are provided for those seeking further information.

The Agency for Toxic Substances and Disease Registry (ATSDR), under the Department of Health and Human Services, is seeking public comments on a proposed study regarding human exposure to chemicals during activities on synthetic turf fields that use tire crumb rubber infill. This study, requiring an extension for additional research delayed by COVID-19, aims to assess exposure to polyaromatic hydrocarbons and will include both users of synthetic turf and natural grass fields for comparison. Public feedback is requested by April 13, 2021, including insights to improve the data collection process and minimize participant burden. The agency outlines a plan to collect detailed activity data and biological specimens from participants to better understand potential exposure risks.